AI Engines For more Details: Perplexity Kagi Labs You
Influenza A Prevention: Rimantadine is approved for the prophylaxis (prevention) of influenza A virus infections. It is particularly effective against influenza A viruses, including certain strains that are resistant to other antiviral medications.
Influenza A Treatment: Rimantadine can also be used for the treatment of influenza A virus infections. It works by inhibiting the replication of the virus within the body, thereby reducing the severity and duration of symptoms associated with the flu.
Symptom Relief: Rimantadine can help alleviate symptoms such as fever, cough, sore throat, fatigue, and body aches that are characteristic of influenza A infections. However, it does not treat symptoms caused by influenza B viruses or other respiratory viruses.
Prophylaxis in High-Risk Individuals: Rimantadine may be prescribed for prophylactic use in individuals at high risk of complications from influenza, such as elderly patients, immunocompromised individuals, or those with underlying medical conditions.
Resistance Monitoring: Due to the potential for the development of resistance, the use of rimantadine should be accompanied by ongoing monitoring for antiviral resistance patterns in circulating influenza strains. Resistance to rimantadine can limit its effectiveness in preventing and treating influenza A infections.
Adverse Effects: Common side effects of rimantadine may include gastrointestinal symptoms such as nausea, vomiting, and abdominal pain. Central nervous system effects such as dizziness, insomnia, and difficulty concentrating may also occur, particularly at higher doses.
Contraindications: Rimantadine is contraindicated in individuals with known hypersensitivity to the drug or its components. It should also be used with caution in patients with a history of seizures or other neurological disorders.
Drug Interactions: Rimantadine may interact with certain medications, such as anticholinergic drugs or medications that affect the central nervous system. Patients should inform their healthcare provider about all medications they are taking before starting rimantadine therapy.
Pregnancy and Lactation: The safety of rimantadine use during pregnancy and lactation has not been well established. Pregnant or breastfeeding women should consult their healthcare provider before using rimantadine.
Pediatric Use: Rimantadine is generally considered safe and effective for use in children aged 1 year and older for the prevention and treatment of influenza A infections. However, dosing adjustments may be necessary based on the child's age and weight.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Anaerobutyricum hallii | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Parabacteroides distasonis | Reduces |
| species | Veillonella atypica | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Akkermansiaceae | family | Decreases |
| 0 | 1 | Veillonella | genus | Decreases |
| 0 | 1 | Eggerthella | genus | Decreases |
| 1 | 0 | Akkermansia | genus | Decreases |
| 0 | 1 | Agathobacter | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 0 | 1 | Collinsella | genus | Decreases |
| 0 | 1 | Dorea | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bifidobacterium | genus | Decreases |
| 0 | 1 | Thomasclavelia | genus | Decreases |
| 0 | 1 | Blautia | genus | Decreases |
| 0 | 1 | Clostridioides | genus | Decreases |
| 0 | 1 | Odoribacter | genus | Decreases |
| 0 | 1 | Clostridium | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | environmental samples | no rank | Decreases |
| 0 | 1 | unclassified Akkermansia | no rank | Decreases |
| 0 | 1 | Clostridium perfringens A | no rank | Decreases |
| 0 | 1 | Clostridium perfringens B | no rank | Decreases |
| 0 | 1 | Clostridium perfringens C | no rank | Decreases |
| 0 | 1 | Clostridium perfringens CPE | no rank | Decreases |
| 0 | 1 | Clostridium perfringens D | no rank | Decreases |
| 0 | 1 | Clostridium perfringens E | no rank | Decreases |
| 1 | 0 | Bacteroides caccae | species | Decreases |
| 1 | 0 | Veillonella parvula | species | Decreases |
| 1 | 0 | Eggerthella lenta | species | Decreases |
| 1 | 0 | Akkermansia muciniphila | species | Decreases |
| 1 | 0 | Agathobacter rectalis | species | Decreases |
| 1 | 0 | Lacrimispora saccharolytica | species | Decreases |
| 1 | 0 | Collinsella aerofaciens | species | Decreases |
| 1 | 0 | Bifidobacterium adolescentis | species | Decreases |
| 1 | 0 | Dorea formicigenerans | species | Decreases |
| 0 | 1 | Veillonella rodentium | species | Decreases |
| 0 | 1 | Veillonella dispar | species | Decreases |
| 1 | 0 | Thomasclavelia ramosa | species | Decreases |
| 1 | 0 | Blautia obeum | species | Decreases |
| 0 | 1 | Veillonella sp. S12025-13 | species | Decreases |
| 0 | 1 | Veillonella nakazawae | species | Decreases |
| 0 | 1 | Eggerthella guodeyinii | species | Decreases |
| 0 | 1 | Veillonella rogosae | species | Decreases |
| 1 | 0 | Clostridioides difficile | species | Decreases |
| 1 | 0 | Bacteroides uniformis | species | Decreases |
| 0 | 1 | Veillonella atypica | species | Decreases |
| 0 | 1 | Parolsenella catena | species | Decreases |
| 0 | 1 | Coprococcus catus | species | Decreases |
| 0 | 1 | Parolsenella massiliensis | species | Decreases |
| 0 | 1 | Dorea longicatena | species | Decreases |
| 0 | 1 | Faecalibacillus intestinalis | species | Decreases |
| 0 | 1 | Wansuia hejianensis | species | Decreases |
| 0 | 1 | Collinsella stercoris | species | Decreases |
| 0 | 1 | Bifidobacterium angulatum | species | Decreases |
| 0 | 1 | Anaerobutyricum hallii | species | Decreases |
| 0 | 1 | Komagataeibacter oboediens | species | Decreases |
| 0 | 1 | Blautia sp. SC05B48 | species | Decreases |
| 1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
| 1 | 0 | Bifidobacterium longum | species | Decreases |
| 0 | 1 | Akkermansia glycaniphila | species | Decreases |
| 0 | 1 | Akkermansia massiliensis | species | Decreases |
| 0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
| 1 | 0 | Odoribacter splanchnicus | species | Decreases |
| 1 | 0 | Clostridium perfringens | species | Decreases |
| 1 | 0 | Streptococcus parasanguinis | species | Decreases |
| 1 | 0 | Bacteroides ovatus | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. infantis | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. longum | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suillum | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suis | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.1 | 0.1 | |
| Acne | 0.1 | -0.1 | |
| ADHD | 1.1 | 0.4 | 1.75 |
| Age-Related Macular Degeneration and Glaucoma | 0.2 | 0 | 0 |
| Allergic Rhinitis (Hay Fever) | 0.6 | 0.9 | -0.5 |
| Allergies | 2.5 | 1.4 | 0.79 |
| Allergy to milk products | 0.8 | 0.4 | 1 |
| Alopecia (Hair Loss) | 0.6 | 0.6 | |
| Alzheimer's disease | 1.8 | 2.1 | -0.17 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1 | 0.5 | 1 |
| Ankylosing spondylitis | 1.4 | 0.1 | 13 |
| Anorexia Nervosa | 0.3 | 0.5 | -0.67 |
| Antiphospholipid syndrome (APS) | 0.1 | 0.1 | |
| Asthma | 1.6 | 1.7 | -0.06 |
| Atherosclerosis | 0.5 | 0.3 | 0.67 |
| Atrial fibrillation | 1.2 | 0.7 | 0.71 |
| Autism | 2.9 | 2.7 | 0.07 |
| Autoimmune Disease | 0.1 | 0.1 | 0 |
| Barrett esophagus cancer | 0.4 | 0 | 0 |
| benign prostatic hyperplasia | 0.1 | -0.1 | |
| Biofilm | 0.4 | 0.4 | |
| Bipolar Disorder | 0.4 | 0.6 | -0.5 |
| Brain Trauma | 0.4 | 0.2 | 1 |
| Cancer (General) | 0.4 | 1.2 | -2 |
| Carcinoma | 1.1 | 0.8 | 0.38 |
| Celiac Disease | 0.7 | 1.3 | -0.86 |
| Cerebral Palsy | 0.9 | 0.2 | 3.5 |
| Chronic Fatigue Syndrome | 1.7 | 2.4 | -0.41 |
| Chronic Kidney Disease | 2.1 | 0.9 | 1.33 |
| Chronic Lyme | 0.1 | 0.1 | 0 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.4 | 0.4 | 0 |
| Chronic Urticaria (Hives) | 0.4 | 0.5 | -0.25 |
| Coagulation / Micro clot triggering bacteria | 0 | 0.1 | 0 |
| Cognitive Function | 0.7 | 0.2 | 2.5 |
| Colorectal Cancer | 0.8 | 0.7 | 0.14 |
| Constipation | 0.1 | 0.1 | 0 |
| Coronary artery disease | 0.6 | 1.2 | -1 |
| COVID-19 | 4.1 | 5.2 | -0.27 |
| Crohn's Disease | 1.9 | 2.1 | -0.11 |
| Cushing's Syndrome (hypercortisolism) | 0.1 | -0.1 | |
| cystic fibrosis | 0.8 | -0.8 | |
| deep vein thrombosis | 0.2 | 0.1 | 1 |
| Denture Wearers Oral Shifts | 0.6 | 0.6 | |
| Depression | 3.4 | 3.5 | -0.03 |
| Dermatomyositis | 0 | 0.1 | 0 |
| Eczema | 0.4 | 0.6 | -0.5 |
| Endometriosis | 0.6 | 0.4 | 0.5 |
| Eosinophilic Esophagitis | 0.4 | -0.4 | |
| Epilepsy | 0.9 | 1.1 | -0.22 |
| erectile dysfunction | 0.2 | 0.1 | 1 |
| Fibromyalgia | 0.9 | 0.4 | 1.25 |
| Functional constipation / chronic idiopathic constipation | 0.5 | 1 | -1 |
| gallstone disease (gsd) | 0.7 | 0.4 | 0.75 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.4 | 0.6 | -0.5 |
| Generalized anxiety disorder | 0.7 | 0.6 | 0.17 |
| giant cell arteritis | 0 | 0 | |
| Glioblastoma | 0 | 0 | |
| Gout | 1 | 0.3 | 2.33 |
| Graves' disease | 0.9 | 1.2 | -0.33 |
| Gulf War Syndrome | 0.2 | 0.9 | -3.5 |
| Halitosis | 0.5 | 0 | 0 |
| Hashimoto's thyroiditis | 1.3 | 0.5 | 1.6 |
| Heart Failure | 0.3 | 1.1 | -2.67 |
| hemorrhagic stroke | 0.2 | 0.2 | |
| Hidradenitis Suppurativa | 0.1 | 0.4 | -3 |
| High Histamine/low DAO | 0.1 | 0.1 | 0 |
| hypercholesterolemia (High Cholesterol) | 0.1 | 0.5 | -4 |
| hyperglycemia | 0.7 | 1.1 | -0.57 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.2 | 2 |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 1.5 | 1.2 | 0.25 |
| Hypothyroidism | 0.2 | 0.5 | -1.5 |
| Hypoxia | 0.8 | 0.8 | |
| IgA nephropathy (IgAN) | 0.4 | 1.4 | -2.5 |
| Inflammatory Bowel Disease | 2.7 | 3.5 | -0.3 |
| Insomnia | 0.9 | 1.6 | -0.78 |
| Intelligence | 0.5 | 0.5 | |
| Intracranial aneurysms | 0.3 | 0.2 | 0.5 |
| Irritable Bowel Syndrome | 3.4 | 1.8 | 0.89 |
| ischemic stroke | 0.9 | 0.4 | 1.25 |
| Liver Cirrhosis | 2.3 | 1.7 | 0.35 |
| Long COVID | 2.8 | 2.6 | 0.08 |
| Lung Cancer | 0.6 | 0.9 | -0.5 |
| Mast Cell Issues / mastitis | 0 | 0.1 | 0 |
| ME/CFS with IBS | 0 | 1.2 | 0 |
| ME/CFS without IBS | 0.9 | 1 | -0.11 |
| membranous nephropathy | 0 | 0 | |
| Menopause | 0.8 | 0.2 | 3 |
| Metabolic Syndrome | 2.4 | 2.5 | -0.04 |
| Mood Disorders | 4.3 | 3.2 | 0.34 |
| multiple chemical sensitivity [MCS] | 0.6 | 0.1 | 5 |
| Multiple Sclerosis | 2.6 | 1.4 | 0.86 |
| Multiple system atrophy (MSA) | 0.7 | 0.2 | 2.5 |
| myasthenia gravis | 0 | 0 | 0 |
| neuropathic pain | 0.3 | 0.5 | -0.67 |
| Neuropathy (all types) | 0.6 | 0.1 | 5 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.1 | 0.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1 | 2.3 | -1.3 |
| NonCeliac Gluten Sensitivity | 1.3 | 0.2 | 5.5 |
| Obesity | 3.4 | 2.5 | 0.36 |
| obsessive-compulsive disorder | 1.2 | 1.3 | -0.08 |
| Osteoarthritis | 0.8 | 0.5 | 0.6 |
| Osteoporosis | 0.8 | 0.9 | -0.13 |
| pancreatic cancer | 0.1 | 0 | 0 |
| Parkinson's Disease | 2.6 | 2.4 | 0.08 |
| Polycystic ovary syndrome | 0.7 | 0.7 | 0 |
| Postural orthostatic tachycardia syndrome | 0 | 0.1 | 0 |
| Premenstrual dysphoric disorder | 0.4 | 0 | 0 |
| primary biliary cholangitis | 0.6 | 0.4 | 0.5 |
| Primary sclerosing cholangitis | 1.4 | 0.5 | 1.8 |
| Psoriasis | 1.7 | 1.1 | 0.55 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.2 | 1.7 | 0.29 |
| Rosacea | 0.1 | 0 | 0 |
| Schizophrenia | 3.2 | 1 | 2.2 |
| sensorineural hearing loss | 0.1 | 0.1 | |
| Sjögren syndrome | 1.3 | 1.3 | 0 |
| Sleep Apnea | 0.4 | 0.5 | -0.25 |
| Slow gastric motility / Gastroparesis | 0.5 | 0.1 | 4 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.5 | 0.1 | 4 |
| Stress / posttraumatic stress disorder | 0.7 | 1.5 | -1.14 |
| Systemic Lupus Erythematosus | 1 | 0.7 | 0.43 |
| Tic Disorder | 0.1 | 0.5 | -4 |
| Tourette syndrome | 0.4 | 0.1 | 3 |
| Type 1 Diabetes | 1.2 | 0.9 | 0.33 |
| Type 2 Diabetes | 2.6 | 2.3 | 0.13 |
| Ulcerative colitis | 1.3 | 1.4 | -0.08 |
| Unhealthy Ageing | 1.1 | 0.9 | 0.22 |
| Vitiligo | 0.3 | 0.4 | -0.33 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
